Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P512: A PHASE 1B/2 STUDY OF TP...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS

Bibliographic Details
Main Authors: Alice Mims, Ying Huang, Eric Eisenmann, Shelley Orwick, Daelynn Buelow, Ronan Swords, Joshua Zeidner, Matthew Foster, Tara L. Lin, Maria Baer, Yazan Madanat, Tibor Kovacsovics, Robert Redner, Zeina Al-Mansour, Mona Stefanos, Molly Martycz, Franchesca Druggan, Timothy Chen, Ashley Yocum, Uma Borate, Brian Druker, Amy Burd, Ross Levine, Sharyn Baker, John C. Byrd
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000968956.29381.19
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000968956.29381.19

Similar Items

  • TP-0903 is active in models of drug-resistant acute myeloid leukemia
    by: Jae Yoon Jeon, et al.
    Published: (2020-12-01)
  • TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
    by: Marianna B. Ruzinova, et al.
    Published: (2019-08-01)
  • Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    by: Mirko Terragno, et al.
    Published: (2024-01-01)
  • Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block
    by: Jiexian Ma, et al.
    Published: (2025-02-01)
  • Hypoxia Reporter Element Assay
    by: Daelynn Buelow, et al.
    Published: (2018-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs